Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * If unavailable, exceptions may be granted with study principal investigator (PI) approval * Age: \>= 18 to 80 years * Eastern Cooperative Oncology Group =\< 2 * Diagnosis of MCL established by histologic assessment including one of the following: * Immunohistochemistry of the biopsy * Flow cytometry of the biopsy * Evidence of t(11;14) translocation involving the cyclin D1 gene by fluorescence in situ hybridization (FISH), and/or cyclin D1 expression by immunohistochemistry (IHC) unless disease is morphologically consistent with MCL and has IHC expression of SOX11 * Requiring treatment for MCL, and for which no prior systemic anticancer therapies have been received * Local radiotherapy not exceeding a total dose of 20 Gy at least 2 weeks prior the first dose of study therapy is allowed * Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL * Asymptomatic patients with blastoid or pleomorphic variant can be enrolled * High risk features as classified by Jain et al. * Blastoid/pleomorphic variants * Ki67 \>= 50% * Presence of a TP53 mutation defined by either molecular testing or IHC * del (17p) by FISH * Complex karyotype * High-risk Mantle Cell Lymphoma …